论文部分内容阅读
目的分析探讨急性心肌梗死静脉溶栓治疗的临床疗效。方法选择急性心肌梗死患者96例,随机分为观察组和对照组各48例。对照组采用急性心肌梗死常规治疗,观察组采用尿激酶溶栓治疗。观察两组患者再通情况和治疗后并发症、病死率。结果观察组在6h内和6～12h内以及总的再通率均高于对照组,差异有统计学意义(P<0.05);对照组的病死率、并发症均高于观察组,差异有统计学意义(P<0.05)。结论尿激酶溶栓治疗急性心肌梗死可以显著改善患者的预后,提高血管的再通率。
Objective To analyze the clinical effect of intravenous thrombolysis in patients with acute myocardial infarction. Methods 96 patients with acute myocardial infarction were randomly divided into observation group and control group, 48 cases each. The control group was treated with routine treatment of acute myocardial infarction, and the observation group was treated with urokinase thrombolysis. Two groups of patients recanalization and post-treatment complications and mortality were observed. Results The observation group within 6h and 6 ~ 12h and the total recanalization rate were higher than the control group, the difference was statistically significant (P <0.05); the control group mortality and complications were higher than the observation group, the difference was Statistical significance (P <0.05). Conclusion Urokinase thrombolytic therapy of acute myocardial infarction can significantly improve the prognosis of patients and improve the recanalization rate of blood vessels.